Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer

BACKGROUND: Both hormonal therapy (HT) and maintenance capecitabine monotherapy (MCT) have been shown to extend time to progression (TTP) in patients with metastatic breast cancer (MBC) after failure of taxanes and anthracycline-containing regimens. However, no clinical trials have directly compared...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xue-Lian, Du, Feng, Hong, Ruo-Xi, Wang, Jia-Yu, Luo, Yang, Li, Qing, Fan, Ying, Xu, Bing-He
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845336/
https://www.ncbi.nlm.nih.gov/pubmed/27112139
http://dx.doi.org/10.1186/s40880-016-0101-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845336/
https://www.ncbi.nlm.nih.gov/pubmed/27112139
http://dx.doi.org/10.1186/s40880-016-0101-7

Ejemplares similares